



Appointment of Dr David Brookes as Non-Executive Director

Brisbane 10 April 2019: Factor Therapeutics (ASX:FTT, the “Company”) is pleased to announce the appointment of Dr David Brookes as Non-Executive Director.

Dr Brookes has extensive experience in the health and biotechnology industries and is currently a Non-Executive director of Anataro Ltd (ASX:ANR). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI \$9B biotech company) in June 2018.

In addition to his directorships in listed biotechnology companies, Dr Brookes is currently Non-Executive Chairman of a private health services company, the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant.

Dr Brookes, MBBS (Adelaide), is a Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors.

“We are extremely pleased that such a well-respected and highly experienced medical professional as Dr Brookes is willing to join our Board at this time when we are focused on expanding our asset base with a new opportunity in the biotechnology area. His extensive experience in biotechnology will be of great value to the company now and in the future” said Dr Cherrell Hirst, Chairman.

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson

Factor Therapeutics Limited

r.wilson@factor-therapeutics.com